This agent cancauseendometrialcancer, but hasbone densityprotective effectBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyPreferredfrequencyof GnRHagonistsDuration of timepatients willtakeabemaciclib inearly stagediseaseThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis drugclass are thebackbone ofHR+ diseaseThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate The onlysteroidalaromataseinhibitor in itsdrug classThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis treatmentmodality isalwayscombined withlumpectomysurgeryI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Based onOncotype DX,a score of 35will receivethis treatmentThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression 1%Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agentshould beinitiated withneratinib for thefirst 8 weeksPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent cancauseendometrialcancer, but hasbone densityprotective effectBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyPreferredfrequencyof GnRHagonistsDuration of timepatients willtakeabemaciclib inearly stagediseaseThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis drugclass are thebackbone ofHR+ diseaseThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate The onlysteroidalaromataseinhibitor in itsdrug classThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis treatmentmodality isalwayscombined withlumpectomysurgeryI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Based onOncotype DX,a score of 35will receivethis treatmentThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression 1%Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agentshould beinitiated withneratinib for thefirst 8 weeksPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPreferredregimen forHR+ diseasefor frail/elderlypatients

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. This agent can cause endometrial cancer, but has bone density protective effect
  2. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  3. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  4. Preferred frequency of GnRH agonists
  5. Duration of time patients will take abemaciclib in early stage disease
  6. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  7. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  8. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  9. This drug class are the backbone of HR+ disease
  10. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  11. This subtype of breast cancer has the lowest relative 5-year survival rate
  12. The only steroidal aromatase inhibitor in its drug class
  13. This agent can be added to LN+ HER2+ disease given with trastuzumab
  14. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  15. This treatment modality is always combined with lumpectomy surgery
  16. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  17. This should be monitored routinely every 3-4 months while receiving trastuzumab
  18. Based on Oncotype DX, a score of 35 will receive this treatment
  19. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  20. 1%
  21. Patients with HER2+ disease continue targeted therapy for this duration
  22. This agent should be initiated with neratinib for the first 8 weeks
  23. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  24. Preferred regimen for HR+ disease for frail/elderly patients